Live Updates: COVID-19 Cases
  • World 30,410,591
    Confirmed: 30,410,591
    Active: 7,366,124
    Recovered: 22,092,948
    Death: 951,519
  • USA 6,879,675
    Confirmed: 6,879,675
    Active: 2,521,131
    Recovered: 4,156,240
    Death: 202,304
  • India 5,228,478
    Confirmed: 5,228,478
    Active: 1,018,231
    Recovered: 4,125,742
    Death: 84,505
  • Brazil 4,457,443
    Confirmed: 4,457,443
    Active: 569,330
    Recovered: 3,753,082
    Death: 135,031
  • Russia 1,091,186
    Confirmed: 1,091,186
    Active: 170,784
    Recovered: 901,207
    Death: 19,195
  • Peru 750,098
    Confirmed: 750,098
    Active: 124,439
    Recovered: 594,513
    Death: 31,146
  • Mexico 684,113
    Confirmed: 684,113
    Active: 123,518
    Recovered: 488,416
    Death: 72,179
  • South Africa 655,572
    South Africa
    Confirmed: 655,572
    Active: 54,497
    Recovered: 585,303
    Death: 15,772
  • Spain 625,651
    Confirmed: 625,651
    Active: 595,246
    Recovered: ?
    Death: 30,405
  • Chile 441,150
    Confirmed: 441,150
    Active: 15,080
    Recovered: 413,928
    Death: 12,142
  • Iran 416,198
    Confirmed: 416,198
    Active: 36,741
    Recovered: 355,505
    Death: 23,952
  • France 415,481
    Confirmed: 415,481
    Active: 293,546
    Recovered: 90,840
    Death: 31,095
  • UK 381,614
    Confirmed: 381,614
    Active: 339,909
    Recovered: ?
    Death: 41,705
  • Bangladesh 345,805
    Confirmed: 345,805
    Active: 88,589
    Recovered: 252,335
    Death: 4,881
  • Saudi Arabia 328,720
    Saudi Arabia
    Confirmed: 328,720
    Active: 15,938
    Recovered: 308,352
    Death: 4,430
  • Pakistan 304,386
    Confirmed: 304,386
    Active: 6,295
    Recovered: 291,683
    Death: 6,408
  • Turkey 298,039
    Confirmed: 298,039
    Active: 26,979
    Recovered: 263,745
    Death: 7,315
  • Italy 293,025
    Confirmed: 293,025
    Active: 41,413
    Recovered: 215,954
    Death: 35,658
  • Germany 270,123
    Confirmed: 270,123
    Active: 19,361
    Recovered: 241,300
    Death: 9,462
  • Canada 140,867
    Confirmed: 140,867
    Active: 8,558
    Recovered: 123,109
    Death: 9,200
  • Netherlands 90,047
    Confirmed: 90,047
    Active: 83,774
    Recovered: ?
    Death: 6,273
  • China 85,255
    Confirmed: 85,255
    Active: 165
    Recovered: 80,456
    Death: 4,634
  • Australia 26,861
    Confirmed: 26,861
    Active: 2,169
    Recovered: 23,855
    Death: 837
  • S. Korea 22,783
    S. Korea
    Confirmed: 22,783
    Active: 2,635
    Recovered: 19,771
    Death: 377
  • New Zealand 1,809
    New Zealand
    Confirmed: 1,809
    Active: 70
    Recovered: 1,714
    Death: 25

Blocking TREM2 could eliminate cancer: a new study shows

Author at TechGenyz Science
Scientists Research

A group of researchers at the Washington University School of Medicine in St. Louis has found that the effects of a standard immunotherapy drug to counter cancer could be enhanced by blocking the protein in TREM2.

The study was published in the journal Cell, and this could show a new way for cancer research.

“Essentially, we have found a new tool to enhance tumor immunotherapy,” said senior author Marco Colonna, MD, the Robert Rock Belliveau, MD, Professor of Pathology. “An antibody against TREM2 alone reduces the growth of certain tumors, and when we combine it with an immunotherapy drug, we see a total rejection of the tumor. The nice thing is that some anti-TREM2 antibodies are already in clinical trials for another disease. We have to do more work in animal models to verify these results, but if those work, we’d be able to move into clinical trials fairly easily because there are already a number of antibodies available.”

T cells have the ability to destroy tumor cells, but the tumors survive by forcefully creating a suppressive immune environment that subdues the T cells. Checkpoint inhibition has been used for ages to attack the tumor, but it always fell short of something and proved itself to being not enough when it comes to attacking the tumor. Colonna and Martina Malgora, Ph.D., a postdoctoral researcher, found that the same kind of immune cells, known as macrophages, were also found in tumors where they produce TREM2 and subdues T cells.

Colonna and Molgora along with colleagues Robert D. Schreiber, Ph.D., the Andrew M. and Jane M. Bursky Distinguished Professor; and William Vermi, MD, an immunologist at the University of Brescia tried to find out if the use of TREM2 could reduce immunosuppression and thereby enhance the ability of T cells to attack and kill tumors.

As part of the experiment, the researchers divided mice into four groups; in one group the mice received an antibody that blocked TREM2, the second group was given a checkpoint inhibitor, the third group was given both, and the fourth group was given a placebo. As for the mice who received the TREM2 or the checkpoint inhibitor alone, it turns out that the tumors grew very slowly, and in a few cases, the tumors completely disappeared.

In another research carried out by Ekaterina Esaulova, it was found that blocking TREM2 turned out to be an effective means of boosting T cell activity. This could be huge for cancer research as a whole since macrophages with TREM2 are found in many kinds of cancers.

The researchers will try to expand their TREM2 study into other kinds of cancers to see the results. As mentioned by Colonna, if their animal trial becomes successful, they will surely go into a clinical trial.